The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

Mallinckrodt PLC, the Irish pharmaceutical ... Upon completion of the merger, Olafsson will become CEO of the combined company, and Paul Efron, a member of the Endo board of directors, will ...

with Mallinckrodt shareholders holding the remaining 50.1%. An implied enterprise value of $6.7 billion considers the aligned ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The combined company will be headquartered in Dublin, Ireland, where Mallinckrodt’s HQ is based, following the close of the merger agreement. Mallinckrodt and Endo said the location of the ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

After cash consideration, Mallinckrodt shareholders will own 50.1% of the combined entity on a pro forma basis for an implied pro forma enterprise value of $6.7 billion. See Also: Endo Weighing ...

Two pharmas that filed for bankruptcy protection due to opioid litigation in the US – Mallinckrodt and Endo – are rumoured to be in merger talks. In a new pharmaphorum podcast, web editor ...

Specialty pharmaceutical companies Endo, Inc. (OTC:ENDPQ) and Mallinckrodt (OTC:MNKTQ) announced Thursday plans to combine in a stock and cash transaction worth $6.7B, creating a public firm ...

DUBLIN and MALVERN, Pa. - Mallinckrodt plc and Endo International plc announced a definitive merger agreement in a stock and cash transaction. The deal is set to create a global pharmaceuticals ...

"That helps us." Endo shareholders will get $80 million in cash and own 49.9% of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion, the ...